Chronic kidney disease Urological and Genital Diseases Kidney disease
Conditions
Interventions
Intrarenal artery infusion of CD34+ endothelial progenitor cells
Sponsors
Chang Gung Memorial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 20–80 years old 2. Chronic kidney disease due to hypertension after optimum drug therapy 3. Chronic kidney disease, stage III–IV with stable renal function within 1 year
Exclusion criteria
Exclusion criteria: 1. Younger than 20 years old or older than 80 years old 2. Pregnant or breastfeeding women 3. Infections (e.g., with human immunodeficiency virus [HIV]) 4. Myocardial infarction or congestive heart failure (functional class IV) within 3 months 5. Malignancy 6. Other severe organ failure 7. Life expectancy of less than 1 year 8. End-stage renal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with an improvement of 5 mL/min in creatinine clearance rate after CD34+ cell treatment at baseline and at 1 week, 1 month, 3 months, 6 months, 9 months and 12 months after therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Significant reductions in: 1. Proteinuria, will be measured every day after therapy for 3 days 2. Creatinine, will be measured every day after therapy for 3 days 3. Combined secondary end-point, defined as acute renal failure with requirement for haemodialysis, or death, at 1 week, 1 month, 3 months, 6 months, 9 months and 12 months after therapy | — |
Countries
Taiwan
Contacts
Public ContactHon-Kan Yip
Outcome results
None listed